Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK's China Venture Enters Health Products Sector

This article was originally published in PharmAsia News

Executive Summary

Tianjin Smith Kline & French Lab, which has been focusing on the OTC business for 21 years in China, marked its entry into the country's healthcare product business last month by launching parent company GlaxoSmithKline's Sensodyne toothpaste. GSK's oral health and health food sectors contribute 27 percent each to its total revenue. As the pharmaceutical giant's China joint venture, TSKF will fully operate the local consumer health business and introduce other items including health food in the near feature. TSKF notes that with the domestic market emerging, the time is right to promote such products. However, it will still concentrate on the OTC business during the next five years even as it increases investments in other sectors. (Click here for more - Chinese Language)

You may also be interested in...

TSKF To Enter Consumer Health Sector In China

GlaxoSmithKline has mapped out its global strategy to increase investment in the consumer healthcare sector. In line with the direction, GSK's China joint venture TSKF marketed its first dental health product Sensodyne toothpaste in the country late 2008 (PharmAsia News, Oct. 13, 2008). TSKF said that the move represented a strategic expansion from merely an OTC business to consumer health; focus and investment in the core OTC market will continue. The company recently launched a new headache package for its top OTC earner Fenbid to extend the brand. Capturing a quarter of China's analgesics market, Fenbid contributed RMB 500 million ($73 million) to TSKF's total revenue of RMB 1.6 billion in 2008. (Click here for more - Chinese language)

GSK's Growth Drivers And Cost Containment Offset Pandemic Impact

GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.

L’Oreal’s Mid-COVID Bet Pays Off With Q3 Return To Growth

With many competitor programs on hold during the COVID crisis, L’Oreal dialed up its media investments and launched products over the summer that were postponed from the first quarter, resulting in a return to growth in the firm’s third quarter led by Professional Products and Active Cosmetics.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts